financetom
Business
financetom
/
Business
/
CVS unit must pay $290 million in drug whistleblower lawsuit, judge rules
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CVS unit must pay $290 million in drug whistleblower lawsuit, judge rules
Aug 20, 2025 7:14 AM

Aug 20 (Reuters) - A federal judge ordered CVS Health's ( CVS )

pharmacy benefit manager unit to pay $289.9 million in

damages and penalties after it overcharged Medicare for

prescription drugs.

In a Tuesday decision, Chief Judge Mitchell Goldberg in

Philadelphia federal court tripled to $285 million the damages

he had ordered CVS Caremark to pay in June, citing the federal

False Claims Act. He added a $4.87 million civil fine.

Goldberg rejected CVS' request to pay less, saying that

while CVS Caremark was liable for only two years of overbilling,

evidence at trial "made clear that the fraud was financially

motivated, not the result of some innocent or mistaken belief."

CVS, based in Woonsocket, Rhode Island, said on Wednesday it

plans to appeal.

Last month, a Manhattan federal judge ordered CVS' Omnicare unit

to pay $948.8 million in a separate whistleblower lawsuit

alleging fraudulent billing. CVS plans to appeal that judgment.

Goldberg presided in March over a non-jury trial in the

whistleblower case brought by Sarah Behnke, a former head

actuary for Medicare Part D at Aetna.

She accused CVS Caremark of having caused health insurers

such as Aetna to submit inflated claims since 2010 to the

Centers for Medicare and Medicaid Services (CMS), while

pharmacies such as Rite Aid and Walgreens were paid

less.

CVS argued that the original $95 million in damages was

substantial, and punitive damages should be limited to $95

million.

But the judge said CVS Caremark's fraud not only financially

harmed the government, but diminished public confidence in it.

"CMS relies on companies like Caremark to truthfully and

accurately report Part D drug prices," he wrote. "Caremark's

conduct broke CMS's trust, and as a result, the public's trust

in CMS."

Behnke sued in 2014. CVS bought Aetna four years later.

The False Claims Act lets whistleblowers sue on behalf of

the government and share in recoveries, typically 15% to 30%.

The case is US ex rel Behnke v CVS Caremark Corp et al, U.S.

District Court, Eastern District of Pennsylvania, No. 14-00824.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
SJVN secures 200-MW wind power project at ₹3.24 per unit
SJVN secures 200-MW wind power project at ₹3.24 per unit
Nov 16, 2023
Projected to generate 482 million units in its inaugural year post-commissioning, the cumulative energy generation over a 25-year span is anticipated to reach 12,050 million units. Shares of SJVN Ltd ended at ₹75.17, down by ₹0.50, or 0.66%, on the BSE.
Tata Power Renewable Energy wins 200-MW project in collaboration with SJVN
Tata Power Renewable Energy wins 200-MW project in collaboration with SJVN
Nov 28, 2023
The firm and dispatchable renewable energy (FDRE) project, designed with a hybrid of solar, wind, and battery storage, is aimed at providing a stable and dispatchable energy supply during peak hours. Shares of Tata Power Company Ltd ended at ₹270.75, up by ₹12.60, or 4.88%, on the BSE.
This sustainable jewellery brand is luring some women away from gold
This sustainable jewellery brand is luring some women away from gold
Oct 30, 2023
Aulerth's offerings range from ₹5,000 to as high as ₹2.8 lakh. Are women willing to spend this much on jewellery made from scrap? Founder and CEO Vivek Ramabhadran definitely believes so. Aulerth produces couture-inspired pieces in association with designers like JJ Valaya, Suneet Varma, among others. It has reported 33% repeat customers in the past year and expects a spike to 40% soon.
Suzlon's S144–3 MW wind turbines get big boost from Indian government
Suzlon's S144–3 MW wind turbines get big boost from Indian government
Nov 15, 2023
Th Suzlon wind turbines received the RLMM (Revised List of Models & Manufacturers) listing from the Ministry of New and Renewable Energy, marking an important milestone for the successful commercialisation of the product. Shares of Suzlon Energy Ltd ended at ₹40.49, up by ₹1.85, or 4.79%, on the BSE.
Copyright 2023-2026 - www.financetom.com All Rights Reserved